The results of the mentioned studies elucidate that use of HDAC inhibitors (TSA and VPA) could lead to histone acetylation of Notch1, leading to a higher Notch1 protein expression and subsequent suppression of SCLC growth. The gene discussed is NOTCH1; the disease is small cell lung carcinoma.